TipRanks
Advertisement
Advertisement

GNLX Stock Latest News

Genelux assumed with a Buy at Lucid Capital
The FlyGenelux assumed with a Buy at Lucid Capital
1d ago
GNLX
Genelux publishes case report from dose escalation portion of OLVI-VEC-202-SCLC
PremiumThe Fly
Genelux publishes case report from dose escalation portion of OLVI-VEC-202-SCLC
8d ago
GNLX
Genelux reports Q2 EPS (21c), consensus (20c)
PremiumThe Fly
Genelux reports Q2 EPS (21c), consensus (20c)
1M ago
GNLX
Genelux expects cash to fund operations into Q1 of 2027
PremiumThe Fly
Genelux expects cash to fund operations into Q1 of 2027
1M ago
GNLX
Genelux reports Q2 EPS (21c), consensus (20c)
PremiumThe Fly
Genelux reports Q2 EPS (21c), consensus (20c)
1M ago
GNLX
Genelux: Undervalued Oncolytic Virus Leader as Olvi-Vec Nears Key Phase 3 Ovarian Cancer Catalyst
PremiumRatingsGenelux: Undervalued Oncolytic Virus Leader as Olvi-Vec Nears Key Phase 3 Ovarian Cancer Catalyst
1M ago
GNLX
Buy Rating Reaffirmed on Olvi-Vec Progress and Data Outlook; $31 Price Target Maintained
Premium
Ratings
Buy Rating Reaffirmed on Olvi-Vec Progress and Data Outlook; $31 Price Target Maintained
4M ago
GNLX
Genelux reports Q1 EPS (20c), consensus (19c)
Premium
The Fly
Genelux reports Q1 EPS (20c), consensus (19c)
4M ago
GNLX
Buy Rating Backed by Pivotal Olvi-Vec Ovarian Cancer Trial Progress and Multi-Indication Upside Potential
PremiumRatings
Buy Rating Backed by Pivotal Olvi-Vec Ovarian Cancer Trial Progress and Multi-Indication Upside Potential
6M ago
GNLX
Genelux price target lowered to $20 from $23 at Benchmark
PremiumThe Fly
Genelux price target lowered to $20 from $23 at Benchmark
6M ago
GNLX
Genelux: Advancing Olvi-Vec Pivotal Program and Manufacturing Readiness Underpin Buy Rating and Long-Term Value Upside
PremiumRatings
Genelux: Advancing Olvi-Vec Pivotal Program and Manufacturing Readiness Underpin Buy Rating and Long-Term Value Upside
6M ago
GNLX
Genelux Establishes $100 Million At-The-Market Equity Program
PremiumCompany Announcements
Genelux Establishes $100 Million At-The-Market Equity Program
6M ago
8K
GNLX
Genelux Updates Corporate Presentation for Investors and Stakeholders
PremiumCompany AnnouncementsGenelux Updates Corporate Presentation for Investors and Stakeholders
8M ago
8K
GNLX
Genelux Announces Underwritten Public Offering to Raise Capital
Premium
Company Announcements
Genelux Announces Underwritten Public Offering to Raise Capital
8M ago
8K
GNLX
Genelux prices 6.67M shares at $3.00 in underwritten public offering
Premium
The Fly
Genelux prices 6.67M shares at $3.00 in underwritten public offering
8M ago
GNLX
Genelux announces common stock offering, no amount given
PremiumThe Fly
Genelux announces common stock offering, no amount given
8M ago
GNLX
Genelux data update indicates disease early control, says H.C. Wainwright
PremiumThe Fly
Genelux data update indicates disease early control, says H.C. Wainwright
9M ago
GNLX
Maintaining Buy on Genelux: Early Olvi-Vec Data Signal Differentiated Potential in Relapsed/Refractory Lung Cancer
PremiumRatings
Maintaining Buy on Genelux: Early Olvi-Vec Data Signal Differentiated Potential in Relapsed/Refractory Lung Cancer
9M ago
GNLX
Genelux Reports Encouraging Interim Data for Olvi-Vec Trials
PremiumCompany Announcements
Genelux Reports Encouraging Interim Data for Olvi-Vec Trials
9M ago
8K
GNLX
Genelux reports interim data of systemic administration of Olvi-Vec
PremiumThe FlyGenelux reports interim data of systemic administration of Olvi-Vec
9M ago
GNLX
Genelux Appoints Veteran Oncologist Jason Litten as CMO
Premium
Company Announcements
Genelux Appoints Veteran Oncologist Jason Litten as CMO
9M ago
8K
GNLX
Genelux appoints Jason Litten as CMO
Premium
The Fly
Genelux appoints Jason Litten as CMO
9M ago
GNLX

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >